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Abstract 
Background: More accurate predictive and prognostic biomarkers for patients with colorectal cancer (CRC) prima-
ries or colorectal liver metastasis (CLM) are needed. Outside clinical trials, the translational integration of emerging 
pathways and novel techniques should facilitate exploration of biomarkers for improved staging and prognosis.
Methods: An observational study exploring predictive and prognostic biomarkers in a population-based, consecu-
tive cohort of surgically treated colorectal cancers and resected colorectal liver metastases. Long-term outcomes 
will be cancer-specific survival, recurrence-free survival and overall survival at 5 years from diagnosis. Beyond routine 
clinicopathological and anthropometric characteristics and laboratory and biochemistry results, the project allows 
for additional blood samples and fresh-frozen tumour and normal tissue for investigation of circulating tumour cells 
(CTCs) and novel biomarkers (e.g. immune cells, microRNAs etc.). Tumour specimens will be investigated by immuno-
histochemistry in full slides. Extracted DNA/RNA will be analysed for genomic markers using specific PCR techniques 
and next-generation sequencing (NGS) panels. Flow cytometry will be used to characterise biomarkers in blood. Col-
laboration is open and welcomed, with particular interest in mutual opportunities for validation studies.
Status and perspectives: The project is ongoing and recruiting at an expected rate of 120–150 patients per year, 
since January 2013. A project on circulating tumour cells (CTCs) has commenced, with analysis being prepared. Inves-
tigating molecular classes beyond the TNM staging is under way, including characteristics of microsatellite instability 
(MSI) and elevated microsatellite alterations in selected tetranucleotides (EMAST). Hot spot panels for known muta-
tions in CRC are being investigated using NGS. Immune-cell characteristics are being performed by IHC and flow 
cytometry in tumour and peripheral blood samples. The project has ethical approval (REK Helse Vest, #2012/742), 
is financially supported with a Ph.D.-Grant (EMAST project; Folke Hermansen Cancer Fund) and a CTC-project (Nor-
wegian Research Council; O. Nordgård). The ACROBATICC clinical and molecular biobank repository will serve as a 
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Background
Colorectal cancer represents a formidable health burden 
worldwide with an expected 60 % increase towards 2030 
[1]. Currently, CRC ranges as the second most frequent 
cancer in both genders in the Western world. Despite an 
increasingly favourable prognosis due to stepwise pro-
gression in surgical and oncological management [2], still 
about 40–50 % will develop metastasis and die from the 
disease. The liver is the most frequent site for metastasis, 
followed by the lungs, and is also the rate-limiting organ 
step for long-term survival. For non-metastatic disease, 
prognosis is guided through the tumour-node-metasta-
sis (TNM)-system, which heavily relies on the status of 
lymph nodes for current staging [3, 4]. Further, node sta-
tus may vary with the underlying molecular composition 
of primary tumour [5, 6]. Also, more refined node-exam-
ination including ultrastaging by immunohistochemistry, 
sentinel node techniques or use of molecular markers to 
identify malignant cells have not yielded a higher pre-
cision overall [7, 8]. Furthermore, other methods and 
techniques of staging patients, such as the use of “liquid 
biopsies” i.e. by investigating circulating tumour cells 
(CTCs) or other tumour constituents in peripheral blood 
(e.g. microRNAs), may prove to have higher prognostic 
and predictive value in both primary and metastatic CRC 
[9–12]. Notably, well-described molecular routes of pro-
gression in CRC have been linked to specific prognosis 
and outcomes, including microsatellite instability (MSI), 
CpG-island methylator phenotype (CIMP) and chromo-
somal instability (CIN) [13–17].
While the TNM is the best staging system at hand for 
clinical decision making, the TNM system is known to 
be imperfect [4], and substantial over- and undertreat-
ment results from failure to accurately predict disease 
outcomes. Indeed, increased knowledge of cancer het-
erogeneity has led researchers and clinicians alike to 
pursue better ways of stratifying therapy to individual 
risk and effects response and efficacy of therapy [18]. 
One suggested consensus taxonomy has emerged for 
novel risk-groups [19], however these have yet to be 
implemented in clinical practice. Variation in definition 
of common denominators for disease stratification may 
be due to a number of reasons, including heterogene-
ous patient groups investigated; investigations done on 
patients recruited to randomized trial with strict inclu-
sion criteria; variation in tumour sampling, and; vari-
ation in molecular analyses and techniques, to mention 
but a few [14, 20–22]. Thus, exploring biomarkers and 
the described genetic and epigenetic pathways in CRC 
[23, 24] by well-defined population cohorts with access to 
biobanking beyond routine samples is crucial (Fig. 1).
The aim of this prospective project is to facilitate pro-
spective accrual of patients with snap-frozen blood sam-
ples and fresh-frozen tissue outside routine clinical care, 
for more refined molecular evaluation (Fig.  1). For one, 
we will explore the role of microsatellite instability (MSI) 
and specifically a form found in tetranucleotide repeats 
(elevated microsatellite alterations in selected tetranucle-
otides; EMAST), which is found at varying frequencies 
in several cancers [25]. EMAST is a less-well described 
molecular trait in CRC, however, recent data point to a 
prognostic role and as a potential modulator of cancer 
biology [26–28]. The role of MSI and EMAST in rela-
tion to presently well-described prognostic mutations, 
such as KRAS and BRAF [29, 30], is not well described. 
Also, investigation into putative mechanisms leading to 
EMAST and the consequence for a predictive and prog-
nostic role is warranted. Second, a cohort of consecutive 
patients will be evaluated for CTCs in resectable stage I–
III CRC for its prognostic value. Third, as the role of the 
immune system is increasingly recognized as an integral 
component to carcinogenesis, cancer biology and patient 
prognosis [31–33], the project will investigate elements 
of the immune system in tumour samples as well as in 
peripheral blood. Finally, additional expansion of related 
projects are emerging with novel techniques, particularly 
with the availability of next-generation sequencing. Here 
we present the study design and protocol for a popula-
tion-based translational cancer research project.
Methods
Study ethics approval
The project and research biobank has been approved by 
the Regional Ethics Committee of the Western Health 
Authority (REK Helse Vest, #2012/742) and by the Insti-
tutional review board (Helse Stavanger HF Protocol 
Record #29034/2012). The project has been registered at 
www.ClinicalTrials.gov NCT#01762813.
long-term source for novel exploratory analysis and invite collaborators for mutual validation of promising biomarker 
results. The project aims to generate results that can help better discern prognostic groups in stage II/III cancers; 
explore prognostic and predictive biomarkers, and help detail the biology of colorectal liver metastasis for better 
patient selection and tailored treatment. The project is registered at http://www.ClinicalTrials.gov NCT01762813.
Keywords: Biomarker, Cancer, Population-based, Translational research, Colorectal cancer, Liver metastasis, 
Circulating tumour cells, Genetics
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Consenting
Patients are informed and consented in the surgery out-
patient clinic or, if directly admitted, in the surgical ward, 
before admission for surgery. A trained research nurse 
certified in Good Clinical Practice does consenting of 
patients and registration.
Study population
Stavanger University Hospital serves as the only hospi-
tal for a population of about 350,000 inhabitants in the 
South-Western part of Norway. The population is pre-
dominant of Caucasian origin, the average population 
age slightly younger than the national average. Socioec-
onomic differences are not extreme in the country; the 
life expectancy is just below 80 years for men and about 
81 years for women. With no other competing hospitals 
in the region and a social security system ensuring equal 
care for all patients, the study population allows for relia-
ble, unselected, population-based and representative data 
sampling with little risk of bias.
We have previously reported epidemiological charac-
teristics to other disease categories based on the same 
non-selected, unbiased conditions, which should validate 
the methodology to the current population-based per-
spective [34–39].
With low migration in the region, long-term follow 
up is feasible and allows for high precision in catching 
new events (disease related or other) with impact on 
Fig. 1 The ACROBATICC project flow sequence and rationale for cancer biology investigation. a Illustrated is a simple workflow of patients’ recruit-
ment and samples of blood (red vials) and tissues (blue vials) from initial diagnosis, before and after surgery and during follow up. Overall, disease-
free and cancer-specific survival will be analysed at 5 years. b Illustrated are the specific levels of patient information gathered for prognostic and 
predictive use, ranging from clinicopathological characteristics (such as sex, age, body weight and height) to genetic and epigenetic mechanisms 
(including microsatellite instability; CpG-island methylator phenotypes and chromosomal instability) and specific tumour-host interactions (such 
as immune-response in tumor; cancer metabolism and role of circulating tumor cells). With access to newer techniques and development of novel 
hypothesis, the project will allow for exploration of other predictors, as well as serve as external validation cohort in collaborative research
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outcomes, as previously reported [40, 41]. The risk of 
loosing patients to long-term follow-up is thus minimal.
All Norwegian citizens have a unique 11-digit social 
security number that allows identification through the 
hospital electronic hospital records with national regis-
tries, including the Norwegian Patient Register and the 
Cancer Registry of Norway. All CRC patients are regis-
tered to the National Colorectal Cancer Registry via an 
electronic template record form. The study will comply to 
the strengthening the reporting of observational studies 
in epidemiology (STROBE) recommendations on what 
should be included in an accurate and complete report of 
any observational study [42].
Inclusion and exclusion criteria
All consecutive patients diagnosed with operable pri-
mary or metastatic colorectal cancer and able to 
provide informed, written consent are included. Partici-
pants can at any time withdraw from the study without 
need for providing any explanation for the withdrawal, 
upon which the records will be destroyed and deleted. 
Excluded are patients presenting as emergencies and 
unable to consent, or patients unable to understand oral 
and written Norwegian or, patients whose cognitive sta-
tus does not allow for informed consent.
Study period
The study commenced in January 2013 and recruit-
ment is ongoing, for an expected closure of recruitment 
in 2018, with final 5-year follow-up to be completed in 
2022.
Study number and sample size
For prognostic information and estimated sufficient num-
bers of patients and events, we expect to recruit about 
150 patients per year. With an expected 35–45 % recur-
rence rate within 5  years of primary diagnosis—which 
is expected from previous regional and national data of 
curatively resected CRC in Norway [2, 40, 43]—and, an 
accrual commencing over at least 5 years (2013–2018) we 
expect to have about 750 patients with operable primary 
and/or metastatic CRC for evaluation at the end of the 
period. In stage I-III CRC, the recurrence rate at 35–45 % 
by 5 years [2, 40, 43] should yield appropriate number of 
events (cancer-specific survival) for creation of test-sets, 
validation-sets and prospective evaluation. Recurrence 
rates are expected to be even higher in colorectal liver 
metastasis (>80 % recurrence within 5 years), suggesting 
fewer patients are needed to evaluate the endpoint.
Clinical work‑up and care
The Department of Gastrointestinal Surgery provide 
all clinical work-up and surgical care for patients with 
colorectal cancer and subsequent evaluation for metas-
tases, resectable or non-resectable. Oncologic care is 
provided at the Department of Oncology. All radiologic 
work-up (except PET/CT scans) are performed at the 
Department of Radiology. Specimen evaluation and tis-
sue blocks preparation for routine diagnostics are per-
formed at the Department of Pathology. Routine blood 
tests are analysed at the Department of Clinical Chem-
istry. Storage of research samples (fresh-frozen) are 
archived in an intramural research biorepository at the 
Stavanger University Hospital. Subsequent DNA and 
RNA retrieval and elaborate laboratory work outside 
routine diagnostics are performed at the Laboratory for 
Molecular Biology, except if otherwise stated.
All patient care are performed under the recommended 
national guidelines issued by the multidisciplinary Nor-
wegian Gastrointestinal Cancer Group (NGICG), for 
both colorectal cancer (NGICG-CRC) and liver metasta-
sis (NGICG-HPB), respectively.
Collaboration
Interested collaborators are welcome to make contact. 
Discussion is extant with other groups and thus has the 
potential to generate an international cohort for compar-
ison and validation of results. No external collaboration 
is yet confirmed but discussion in progress.
The cohort material will similarly also be available for 
cross-evaluation with other cohorts generated elsewhere, 
and will be beneficial for external validation purposes 
and hypothesis-generating experimental studies.
Samples
Issues to attend to for biomarker research and report-
ing have been addressed in several leading journals [21, 
22]. Consequently, the current study will seek to comply 
and report according to the biospecimen reporting for 
improved study quality (BRISQ) recommendations for all 
tissue sampling and storage in the study [44]. For parts 
of the study relating to clinical prognosis, we will aim to 




Resected specimens are handled at the Department of 
Pathology according to protocol. An electronic tem-
plate is followed and applied for gross examination and 
microscopic description of pathologic features and data 
for staging. Staging is done per the TNM-system (AJCC 
7th edition). Representative tissue slides (resection ends 
or normal tissue distant from primary tumour; several 
tumour slides including most invasive front; all sampled 
lymph nodes) are formalin-fixed paraffin-embedded 
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(FFPE) for routine H&E diagnostics and microscopy. 
Lymph nodes are sampled per protocol and aimed to 
achieve at least 12 nodes and, if less, a ‘lymph node 
revealing solution’ (a mixture composed of 95 % ethanol, 
diethyl ether, glacial acetic acid, and buffered formalin; 
also called GWEF) is applied to mesenteric fat in order to 
enhance node recovery [46].
Frozen fresh tumour tissue and normal sample
Before formalin fixation and immediate upon retrieval of 
the specimen, representative fresh tumour samples are 
obtained (at least three per tumour), stored in meticu-
lously marked vials, and frozen in liquid nitrogen. Time 
is kept to a minimum between resection and delivery at 
Pathology in order to minimize loss of RNA quality [47, 
48], usually delivered by an orderly within 15  min of 
retrieval from the operating room to the laboratory.
For the rare occasional procedures commencing or 
proceeding outside opening hours of the Department 
of Pathology, the surgeon in charge samples the fresh 
tumour biopsies per protocol and provides this in a port-
able insulated box container with dry ice for storage, nor-
mally <12 h. Samples are then collected by a technician 
and processed per protocol as early as possible the next 
morning.
Blood samples
Peripheral blood samples are drawn (usually) from the 
antecubital vein on admission before surgery and on 
the outpatient follow-up appointment, approximately 
4  weeks after surgery. Subsequent blood is drawn if 
patient is readmitted for new surgery for recurrence or 
metastatic disease, and then again if a second curative-
intent surgery (e.g. resection of new large bowel tumour; 
local recurrence; or, metastasectomy) is planned. Blood 
samples are processed to serum and plasma by centrifu-
gation and two vials of full blood (EDTA-containers) are 
frozen and stored in −80 °C freezers together with pro-
cessed samples.
Circulating tumour cell (CTC) detection
Peripheral blood samples (9  ml) are collected in EDTA 
tubes and subjected to density centrifugation within 20 h 
(preferably 2 h) from the collection time. RNA is isolated 
from the peripheral blood mononuclear cell fraction and 
reverse transcribed. Circulating tumour cells (CTCs) are 
then detected indirectly by measuring epithelial-specific 
mRNAs, which are not present in normal blood cells, as 
surrogate markers [12, 49, 50]. mRNA concentrations are 
measured by quantitative reverse-transcription PCR. The 
background levels in blood samples from healthy control 
persons are utilized as a reference material to determine 
which patient samples are positive for CTCs.
DNA/RNA extraction
DNA and RNA are extracted from freshly frozen tumour 
and normal (surgical resection margins or normal tissue 
sampled distant from primary tumour) using the QIA-
CUBE (Qiagen) instrument and dedicated reagents and 
kits, according to manufacturers instructions. Weighted 
15–20  mg of tissue are resuspended in lysis buffer and 
homogenized in the presence of 5  mm Ø steel beads, 
in a TissueLyser LT (Qiagen), at 50  Hz, for 4  min. Two 
consecutive protocols are then used on the QIACUBE 
instrument to extract DNA first, and RNA later (from 
flow through of first protocol) via the use of AllPrep 
DNA/RNA/miRNA Universal Kit. Concentration, purity 
(A260/280) and presence of phenol and protein con-
taminants in the eluted sample (A260/230) are measured 
and noted with a NanoDrop (ThermoFischer) intru-
ment. Extracted DNA and RNA are labelled and stored 
at −80  °C in the aforementioned intramural biobanking 
facility.
Employed molecular techniques
Mentioned examples here are not exclusive, but include:
Immunohistochemistry (IHC)
Antigen retrieval and antibody dilution are optimized 
prior to the study onset for the different antibodies. To 
ensure uniform handling of samples, all sections are 
processed simultaneously. Paraffin sections adjacent to 
the haematoxylin-eosin (H&E) sections used for histol-
ogy are mounted onto Superfrost Plus slides and dried 
overnight at 37 °C followed by 1  h at 60 °C. Sections 
are deparaffinised in xylene and rehydrated in decreas-
ing concentrations of alcohol. Antigen is retrieved using 
Tris–EDTA (pH 9.0) as the retrieval buffer. Endogenous 
peroxidase activity is blocked with a peroxidase-block-
ing reagent. The immune complex is visualized with the 
Dako REAL EnVision Detection System, Peroxidase/
DAB, Rabbit/Mouse (K5007; Dako). Sections are incu-
bated with EnVision/HRP, Rabbit/Mouse for 30  min 
and diaminobenzidine (DAB+) chromogen. The sec-
tions are counterstained with haematoxylin, dehydrated, 
and mounted. All steps are performed using DakoAuto-
stainer and TBS (S1968; Dako) with 0.05 % Tween 20 as 
wash buffer. Quality assessment and scoring of the sam-
ples are executed by an experienced pathologist and with 
use of digital pathology software (Visiopharm) for some 
antibodies.
Candidate markers for investigation are in develop-
ment, and includes (but not limited to) suggested mark-
ers for immune cells (e.g. CD4+, CD8+, CD45RO+) and 
as suggested in the Immunoscore [51], potential mark-
ers of differentiation (e.g. CDX2) in CRC stage subtypes 
[52], and markers related to mechanistic insight, such as 
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MSH3 and its relation to EMAST [53, 54]. Other markers 
will be employed for specific subprojects as needed, e.g. 
for validating protein expression for gene variations.
Flowcytometry
Freshly drawn blood is collected in EDTA coated blood 
vacuum containers. Percentages of human CD4+ and 
CD8+ T-lymphocytes in erythrocyte-lysed whole blood 
are determined by flow cytometry. The antibody kit is 
acquired from BD Biosciences (Cat no: 342417) with CD3 
FITC/CD8 PE/CD45 PerCP/CD4 APC conjugated stain-
ing. Cells are prepared according to protocol and 100 µl 
whole blood is used. BD Pharm Lyse (Cat no: 555899) 
is used at appropriate dilution to lyse erythrocytes. The 
samples are run on an Accuri C6 (BD biosciences) or a 
Cytoflex (Beckman-Coulter) flow cytometer both sys-
tems equipped with a blue and red laser, two light scatter 
detectors, and four fluorescence detectors with optical 
filters optimized for the detection of FITC, PE, PerCP, 
and APC. Further analysis of results is being done using 
the corresponding software (BD Biosciences Accuri C6 
analysis software and CytExpert Beckman-Coulter).
Next generation sequencing (NGS)
Template preparation and chip loading is carried out 
using the Ion Chef™ System. With the use of CRC-spe-
cific, validated custom and commercially available panels, 
targeted DNA ion semiconductor sequencing of tumour 
material is performed on the Ion Torrent™ Personal 
Genome Machine® (PGM, ThermoFischer) platform. 
Data analysis against the reference (human) genome is 
executed in-house with the aid of the Torrent Suite™ and 
Ion Reporter™ softwares.
Statistical analysis and endpoints
The project is exploratory and thus no formal statisti-
cal power has been done. The population-based, obser-
vational, real-life, non-selected cohort will allow for 
adequate power based on the expected recruitment of 
a cohort size of 750 patients, of which an expected one-
third (about 250) will have recurrence or death from 
disease. With the high number of events, this will allow 
for reasonable multivariable adjustments for outcomes. 
For smaller samples in subgroups (e.g. only stage II; or, 
only patients with resected liver metastasis), hypothesis-
generating results will be pursued with appropriate sized 
prospective cohort samples with internal and external 
validation cohorts, where available.
The main endpoints will be cancer-specific, recur-
rence-free and overall survival, which will be analysed 
with Kaplan–Meier figures and log rank test. Explora-
tory analyses will be done using descriptive techniques 
for hypothesis-generating results. For laboratory values 
without established cut-offs, we will apply receiving-
operator characteristics (ROC) analyses for optimal cut-
off determination [55]. For prognostic factors, we will 
apply appropriate multivariable regression analyses for 
appropriately adjusted analyses.
Discussion
The ACROBATICC projects aim to integrate the routine 
clinical work-up and treatment of patients with primary 
CRC and resectable liver metastasis with state-of-the-art 
molecular technology investigations of blood samples 
and tumor tissues. The aim is to explore and identify bet-
ter predictive and prognostic biomarkers that may even-
tually help in clinical decision-making for more precise, 
personalized and tailored treatment. The ACROBATICC 
clinical and molecular biobank repository will serve as 
a long-term source for novel exploratory analysis and 
invite collaborators for mutual validation of promising 
biomarker results. The project aims to generate results 
that can help better discern prognostic groups in stage II/
III cancers; explore prognostic and predictive biomark-
ers, and help detail the biology of colorectal liver metas-
tasis for better patient selection and tailored treatment 
[23, 28, 56].
The role of population-based cancer biobanking is 
increasingly recognized as important for exploratory and 
confirmatory studies at an unselected, population-level. 
While regular diagnostic biobanking [i.e. formalin-fixed 
and paraffin embedded (FFPE) tissue blocks] allow for 
valuable analyses outside routine descriptive data, such 
repositories may have a number of medicolegal and 
laboratory limitations which may be overcome by spe-
cific research-driven projects. The current translational 
cancer research project will allow for further in-depth 
analyses into cancer biology otherwise not available from 
material obtained by routine care.
The use of “liquid biopsy” has gained considerable 
attention as a novel source of biomarkers. Blood-based 
biomarkers could prove to be practical tools for CRC 
detection, as the monitoring of biomarkers in biological 
fluids offers many advantages, including minimal inva-
siveness and easy accessibility [57]. In the current study, 
we will have the opportunity to explore for tumour-spe-
cific markers in blood and tissue that may be related to 
prediction and prognosis of outcome.
Lack of uniform research designs, poor quality con-
trol and large variation in reporting have hampered bio-
marker research and comparison of data in the past. This 
has invariably led to a number of promising but non-
validated biomarkers in past studies. Currently, a large 
number of guidelines and recommendations are avail-
able to instruct, inform and impede better and more uni-
form reporting of results. However, the number of such 
Page 7 of 9Søreide et al. J Transl Med  (2016) 14:192 
guidelines is increasing rapidly [58], with some suggest-
ing there be too many guidelines to possibly comply to. 
However, we believe that a core set of important guides 
help set useful framework for reporting and help avoid 
huge deviation from recommended practice. Evaluation 
of compliance to such guidelines suggest that consider-
able deviation and lack of reporting core data still exist in 
biomarker research studies [59]. Thus, we would seek to 
adhere and comply with the recommendations addressed 
in the protocol and any other relevant recommendations, 
as issued by the EQUATOR network (http://www.equa-
tor-network.org).
Project status
The project is currently recruiting patients and labora-
tory work on the CTCs is ongoing, as well as laboratory 
work on MSI and EMAST in primary tumours. Hot spot 
panels of known CRC mutations with NGS technology is 
being prepared. A pilot, feasibility study to test for same-
time comparison of patients’ circulating immune-cells in 
peripheral blood and comparison to tumour-infiltrating 
cells in the cancer specimen is currently being conducted.
Future aspects
We envision several add-ons to be possible with increases 
resources and manpower in the project. For one, patient 
reported outcomes (PROs) is an increasing are of inter-
est and would yield yet another dimension to the clinical-
translational aspect of the project [60]. Also, the sampled 
biopsies will allow for a number of other experiments and 
analyses, such as exosomic DNA, microRNA and other 
emerging biomarkers. Further, other sampling techniques 
and specimens would be feasible in the future, such as 
sampling and investigating faeces for both genetic and 
epigenetic biomarkers [24], but also investigating the 
microbiome for its putative role in carcinogenesis but 
also possible influence on cancer biology [61, 62]. Last, 
but not least, we would pursue international collabora-
tion for mutual validation of similar ongoing biomarker 
projects [63]. The prospective cohort results will seek 
collaboration for external validation studies but may also 
serve as an external validation cohort for other research 
groups interested in collaboration.
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